

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORLED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: L. E. Crane Examiner #: 65753 Date: 08/04/00  
Art Unit: 1623 Phone Number 30 8-4639 Serial Number: 09/363,748  
Mail Box and Bldg/Room Location: M1; 7E-15 Results Format Preferred (circle): PAPER DISK E-MAIL

**If more than one search is submitted, please prioritize searches in order of need.**

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see copy of claims attached

Inventors (please provide full names): "

Earliest Priority Filing Date: " / /

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search for a method of treating a human for "neurological disorders by administration of uridine or source of uridine and "other compounds including CHOLINE or choline ester (30-33). Disorders are defined in claims 5, 9, 12, 13, 17, 18, 19, 20, 28 also OTHER COMPOUNDS - see claims 30-31, 33, 34, 35.

BEST AVAILABLE COPY

*PLEASE RUSH*  
*Moira Elliott*

## STAFF USE ONLY

Searcher: an  
Searcher Phone #: 4478  
Searcher Location: \_\_\_\_\_  
Date Searcher Picked Up: 8/7  
Date Completed: 8/6  
Searcher Prep & Review Time: 126  
Clerical Prep Time: \_\_\_\_\_  
Online Time: 115

## Type of Search

NA Sequence (#) \_\_\_\_\_  
AA Sequence (#) \_\_\_\_\_  
Structure (#) \_\_\_\_\_  
Bibliographic ☒ \_\_\_\_\_  
Litigation \_\_\_\_\_  
Fulltext \_\_\_\_\_  
Patent Family \_\_\_\_\_  
Other \_\_\_\_\_

## Vendors and cost where applicable

STN ☒ \_\_\_\_\_  
Dialog \_\_\_\_\_  
Questel/Orbit \_\_\_\_\_  
Dr. Link \_\_\_\_\_  
Lexis/Nexis \_\_\_\_\_  
Sequence Systems \_\_\_\_\_  
WWW/Internet \_\_\_\_\_  
Other (specify) \_\_\_\_\_

=> fil hcaold

FILE 'HCAOLD' ENTERED AT 17:31:05 ON 07 AUG 2000  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Point of Contact:  
 Jan [unclear]  
 Librarian-Physical Sciences  
 CM1 1E01 Tel: 308-4496

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING  
 FILE COVERS 1907-1966  
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his l19-

(FILE 'REGISTRY' ENTERED AT 17:16:36 ON 07 AUG 2000)

FILE 'HCAOLD' ENTERED AT 17:23:42 ON 07 AUG 2000

L19 1 S L8  
 L20 632 S URIDIN?  
 L21 5 S L20 AND ?NEUR?  
 L22 6 S L20 AND ?NERV?  
 L23 11 S L21,L22  
 L24 0 S L20 AND (MEMORY OR PICK OR LEWY OR DEMENT? OR SENIL? OR SENES  
 L25 3 S L20 AND (BEHAV? OR EMOTI? OR STRESS? OR PANIC OR ANXIET? OR A

FILE 'HCAOLD' ENTERED AT 17:27:37 ON 07 AUG 2000

FILE 'HCAOLD' ENTERED AT 17:28:41 ON 07 AUG 2000

FILE 'HCAOLD' ENTERED AT 17:28:47 ON 07 AUG 2000

L26 1 S L20 AND (ATAX? OR FRIEDREICH? OR DYSKINES? OR ?THROMBO?)  
 L27 15 S L20 AND (ISCHEM? OR ISCHAEM? OR HYPOX? OR CEREBR? OR BRAIN OR  
 L28 1 S L20 AND (SPINAL OR SPINE OR ANOX? OR MYASTHEN? OR POLIO OR PO

FILE 'HCAOLD' ENTERED AT 17:31:05 ON 07 AUG 2000

=> d all hitstr l28

L28 ANSWER 1 OF 1 HCAOLD COPYRIGHT 2000 ACS  
 AN CA57:10485f CAOLD  
 TI pharmacology of .alpha.-amino acids  
 AU Kowa, Yoshio  
 TI studies on the disturbances caused by dehydrocholic acid on the process of elimination of Bromsulfaein  
 AU Benda, Nello; Gambelunghe, C.  
 TI uridine-5-triphosphate in therapy - (I) cure of neurogenic muscular atrophy, (II) cure of myopathia, myotonia, **myasthenia**, and of asthenic condition  
 AU Coirault, R.; Levy, J.; Michel-Ber, E.; Masbernard, A.; Fonchais, S. D. de la; Mazingant, F.

=> fil hcaplus .

7/31/98  
 Conrad White/MS  
 Railroad Washington

FILE 'HCAPLUS' ENTERED AT 17:45:08 ON 07 AUG 2000  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 7 Aug 2000 VOL 133 ISS 7  
 FILE LAST UPDATED: 6 Aug 2000 (20000806/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in HCAPLUS on STN.

=> d all hitstr tot

L48 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2000 ACS

AN 2000:161074 HCAPLUS

DN 132:203149

TI Compositions and methods using pyrimidine nucleotide precursors for treatment of mitochondrial diseases

IN Von Borstel, Reid W.

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A01N043-04

ICS A61K031-70

CC 1-10 (Pharmacology)

Section cross-reference(s): 33, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000011952	A1	20000309	WO 1999-US19725	19990831 <--
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9960219	A1	20000321	AU 1999-60219	19990831 <--
PRAI	US 1998-144096		19980831 <--		
	WO 1999-US19725		19990831		
AB	Compds., compns., and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a compn. contg. pyrimidine nucleotide precursors in amts. sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.				
ST	mitochondrial disease treatment pyrimidine nucleotide precursor;				

respiratory chain mitochondrial deficiency pyrimidine nucleotide precursor  
therapeutic

IT **Nervous system**  
(**Friedreich's ataxia**; pyrimidine nucleotide  
precursors for treatment of mitochondrial diseases)

IT **Nervous system**  
(**Huntington's chorea**; pyrimidine nucleotide precursors for  
treatment of mitochondrial diseases)

IT Muscle, disease  
(Kearns-Sayre syndrome; pyrimidine nucleotide precursors for treatment  
of mitochondrial diseases)

IT **Brain, disease**  
(Leigh's disease; pyrimidine nucleotide precursors for treatment of  
mitochondrial diseases)

IT **Brain, disease**  
(MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and  
stroke-like episodes); pyrimidine nucleotide precursors for treatment  
of mitochondrial diseases)

IT Muscle, disease  
(MERRF (myoclonic epilepsy assocd. with ragged-red muscle fibers);  
pyrimidine nucleotide precursors for treatment of mitochondrial  
diseases)

IT Disease, animal  
(NARP (**neurogenic** muscle weakness, **ataxia**, and  
retinitis pigmentosa); pyrimidine nucleotide precursors for treatment  
of mitochondrial diseases)

IT **Brain, disease**  
(Rett syndrome; pyrimidine nucleotide precursors for treatment of  
mitochondrial diseases)

IT **Nervous system**  
(**ataxia**; pyrimidine nucleotide precursors for treatment of  
mitochondrial diseases)

IT **Mental disorder**  
(**attention deficit hyperactivity disorder**;  
pyrimidine nucleotide precursors for treatment of mitochondrial  
**diseases**)

IT **Mental disorder**  
(autism; pyrimidine nucleotide precursors for treatment of  
mitochondrial **diseases**)

IT **Nervous system**  
(autonomic, **neuropathy**; pyrimidine nucleotide precursors for  
treatment of mitochondrial diseases)

IT Heart, disease  
(cardiomyopathy, dilating; pyrimidine nucleotide precursors for  
treatment of mitochondrial diseases)

IT Cytoprotective agents  
(cardioprotective; pyrimidine nucleotide precursors for treatment of  
mitochondrial diseases)

IT Muscle  
(cell; pyrimidine nucleotide precursors for treatment of mitochondrial  
diseases)

IT Fatigue, biological  
(chemotherapy-assocd.; pyrimidine nucleotide precursors for treatment  
of mitochondrial diseases)

IT Menopause  
(chemotherapy-induced; pyrimidine nucleotide precursors for treatment  
of mitochondrial diseases)

IT Fatigue, biological  
(chronic fatigue syndrome; pyrimidine nucleotide precursors for  
treatment of mitochondrial diseases)

IT Eye, disease  
(chronic progressive external ophthalmoplegia; pyrimidine nucleotide  
precursors for treatment of mitochondrial diseases)

IT **Brain**  
(corpus striatum, striatal dopamine content; pyrimidine nucleotide  
precursors for treatment of mitochondrial diseases)

IT **Neuron**  
(death; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Nervous system**  
(degeneration; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Neuromuscular diseases**  
(degenerative; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Mutation**  
(deletion; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Appetite**  
(**depressed**; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Development, mammalian postnatal**  
(developmental delay in cognitive, motor, language, executive function, or social skills; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Bladder**  
(diseases, **neurogenic** bladder dysfunction; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Mitochondria**  
(diseases; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Toxins**  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
(excitotoxins; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Liver, disease**  
(failure; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Drugs**  
(gastrointestinal, for **neurogenic** bowel dysfunction; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Eye, disease**  
(hereditary optic atrophy; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Acidosis**  
(lactic acidosis; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Chemotherapy**  
(menopause induced by and fatigue assocd. with; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Diagnosis**  
(mitochondrial disease; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Brain, disease**  
(mitochondrial encephalomyopathy, mitochondrial **neurogastrointestinal**; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Proteins, general, biological studies**  
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
(mitochondrial respiratory chain nuclear-encoded protein components; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Respiration, animal**  
(mitochondrial; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Behavior**  
(motor, developmental delay in cognitive, motor, language, executive function, or social skills; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Heart**

(myocyte; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Muscular dystrophy**  
(myotonic; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Intestine, disease  
(**neurogenic** bowel dysfunction; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Cell death  
(**neuron**; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Cytoprotective agents  
(**neuroprotectants**; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Nerve**  
(optic, optic **neuropathy**; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Nerve**, disease  
(peripheral **neuropathy**; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Mitosis  
(post-mitotic cell death or functional decline; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Aging, animal  
Anti-**Alzheimer's** agents  
Anticonvulsants  
Antimigraine agents  
**Antiparkinsonian** agents  
Cell death  
Cognition enhancers  
Cytoprotective agents  
Drug delivery systems  
**Muscular dystrophy**  
Mutation  
**Nervous** system agents  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Pyrimidine nucleotides  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Mitochondrial DNA  
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Acidosis  
(renal tubular; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Mitochondria  
(respiration; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Antitumor agents  
Cytotoxic agents  
(respiratory chain dysfunction from; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Deafness  
(sensorineural; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT **Behavior**  
(social, developmental delay in cognitive, motor, language, executive function, or social skills; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

IT Disease, animal  
(speech **disorder**, **developmental** delay in cognitive,

- motor, language, executive function, or social skills; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT Hepatitis  
(steatohepatitis; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT Kidney, disease  
(tubular acidosis; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT 33069-62-4, Taxol  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
(**neuropathy** induced by; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT 89-00-9, Quinolinic acid 504-88-1, 3-Nitropropionic acid 28289-54-5, MPTP  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT **58-96-8, Uridine**  
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT 260360-01-8P  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT **58-96-8D, Uridine**, acyl derivs. 65-46-3, Cytidine 65-46-3D, Cytidine, acyl derivs. 65-86-1, Orotic acid 65-86-1D, Orotic acid, esters 127-17-3, Pyruvic acid, biological studies 127-17-3D, Pyruvic acid, esters **987-78-0**, Cytidine **diphosphocholine** 1747-53-1, Ethyl orotate 4105-38-8, 2',3',5'-Tri-O-acetyluridine 260360-02-9 260360-03-0 260360-04-1 260360-05-2 260360-06-3 260360-07-4  
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT 51-61-6, Dopamine, biological studies  
RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT 9000-83-3, Complex V (Mitochondrial electron transport) 9001-16-5, Mitochondrial electron transport complex IV 9027-03-6, Mitochondrial electron transport complex III 9028-04-0, Mitochondrial electron transport complex I 9028-11-9, Mitochondrial electron transport complex II  
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)
- IT 5704-66-5  
RL: RCT (Reactant)  
(reaction; pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

RE.CNT 5

RE

- (1) Bodnar; Biochem J 1995, V305, P817 HCAPLUS
- (2) Dykens, J; Journal of Neurochemistry 1994, V63, P584 HCAPLUS
- (3) Keilbaugh; Molecular Pharmacology 1993, V44(4), P702 HCAPLUS
- (4) Secades; Methods and Findings in Experimental and Clinical Pharmacology 1995, V17(Supplement 1), P1
- (5) van Borstel; US (5470838) A 1995



IT 58-96-8, **Uridine**

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);


**THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

RN 58-96-8 HCAPLUS

CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 58-96-8D, **Uridine**, acyl derivs. 987-78-0,

Cytidine **diphosphocholine**

RL: BAC (Biological activity or effector, except adverse); **THU**


**(Therapeutic use)**; BIOL (Biological study); USES (Uses)

(pyrimidine nucleotide precursors for treatment of mitochondrial diseases)

RN 58-96-8 HCAPLUS

CN Uridine (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 987-78-0 HCAPLUS

CN Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl] ester, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L48 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2000 ACS

AN 2000:98343 HCAPLUS

DN 132:132349

TI Methods using **uridine** or a **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human

**neurological diseases**

IN **Watkins, Carol; Wurtman, Richard J.**  
 PA Massachusetts Institute of Technology, USA  
 SO PCT Int. Appl., 22 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-55  
 ICS A61K031-70; A61K031-235; A61K031-515; A61K031-685  
 CC 1-11 (Pharmacology)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006174	A1	20000210	WO 1999-US17235	19990730
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1998-95002		19980731	<--	
AB	Methods of treating certain <b>neurol.</b> diseases using exogenous <b>uridine</b> or a <b>uridine</b> source alone as a precursor of endogenous cytidine, particularly in the human <b>brain</b> , are disclosed. Methods are also disclosed in which exogenous <b>uridine</b> or a <b>uridine</b> source is combined either with drugs increasing <b>uridine</b> availability or with compds. that serve as a source of <b>choline</b> in phospholipid synthesis.				
ST	<b>uridine</b> cytidine precursor <b>neurol</b> disease treatment; <b>choline</b> source <b>uridine neurol</b> disease treatment				
IT	AIDS (disease) (AIDS <b>dementia</b> complex; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Mental disorder</b> (AIDS <b>dementia</b> ; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Nervous system</b> ( <b>Friedreich's ataxia</b> ; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Nervous system</b> ( <b>Huntington's chorea</b> ; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Mental disorder</b> ( <b>Pick's disease</b> ; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Mental disorder</b> (affective, seasonal; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Brain</b> (aging, <b>memory</b> decline assocd. with; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Mental activity</b> ( <b>alertness</b> ; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Nervous system</b> ( <b>ataxia</b> ; <b>uridine</b> or <b>uridine</b> source for increasing cytidine levels in vivo and treating cytidine-dependent human <b>neurol.</b> diseases)				
IT	<b>Mental disorder</b> ( <b>attention deficit disorder</b> ; <b>uridine</b> or				

*Appl. owned  
work*

uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Aging, animal  
(**brain, memory** decline assocd. with;  
uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Hypoxia, animal  
(**cerebrovascular** disease from; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Brain, disease  
(**cerebrovascular, hypoxia**-caused; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Mental activity  
(**concn. and focus**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT HPLC  
(cytidine-tyrosine sepn. in; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Mental disorder  
(**dementia**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Mental disorder  
(**depression, neurotic**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Mental disorder  
(diffuse **Lewy body disease**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Nervous system  
(**disease**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Behavior  
Emotion  
(**disorder**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Mental disorder  
(**dyslexia**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Spinal cord  
(**injury, behavioral** or **neurol. syndrome** after **anoxia** or; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Mental disorder  
(**mania**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Mental disorder  
(**manic bipolar disorder**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Anxiety  
(**panic**; uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol. diseases**)

IT Nervous system

- (peripheral, disease; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **Poliomyelitis**  
(post-**polio** syndrome; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **Brain, disease**  
(stroke; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **Nervous system**  
(tardive **dyskinesia**; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **Brain, disease**  
(trauma, **behavioral** or **neurol.** syndrome after; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **Anti-ischemic agents**  
**Antidepressants**  
**Antiparkinsonian agents**  
**Antipsychotics**  
**Anxiolytics**  
Blood analysis  
Cognition enhancers  
Movement disorders  
**Muscular dystrophy**  
**Myasthenia gravis**  
**Nervous system agents**  
**Neuromuscular diseases**  
**Schizophrenia**  
**Stress, animal**  
(**uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **Fatty acids, biological studies**  
**Lecithins**  
**Lysophosphatidylcholines**  
**Sphingomyelins**  
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **Biological transport**  
**Kidney**  
(**uridine** renal transport competitors; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT 60-18-4, Tyrosine, analysis  
RL: ARU (Analytical role, unclassified); ANST (Analytical study)  
(cytidine-tyrosine sepn. in HPLC; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT 9030-22-2, **Uridine phosphorylase**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; **uridine** or **uridine** source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)
- IT **58-96-8, Uridine**  
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(**uridine** or **uridine** source for increasing cytidine

levels in vivo and treating cytidine-dependent human **neurol.** diseases)

IT 65-46-3, Cytidine  
RL: ANT (Analyte); BPR (Biological process); ANST (Analytical study); BIOL (Biological study); PROC (Process)

(uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)

IT 54-03-5, Hexobendine 62-49-7, Choline  
67-48-1, Choline chloride 87-67-2,  
Choline bitartrate 563-24-6,  
Glycerophosphatidylcholine 563-24-6D,  
Glycerophosphocholine, acyl derivs. 987-78-0, CDP-  
choline 5909-45-5 5909-45-5D, derivs.  
5983-09-5, 2',3'-Dideoxyuridine 23464-76-8,  
Choline stearate 26287-69-4, L-Uridine  
35898-87-4, Dilazep 153547-98-9

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)

RE.CNT 9

RE

- (1) Bamat, M; WO 8903837 A ✓
- (2) Gallai, V; Ribista di Neuropsichiatria e Scienze Affini 1995
- (3) Luca, D; US 4960759 A 1990 ✓
- (4) Myers, C; Pharmacology biochemistry and Behavior 1995
- (5) Page, T; Proc Natl Acad Sci U S A 1997 HCAPLUS
- (6) Piazza, C; WO 9745127 A1 HCAPLUS
- (7) Sommadossi; US 5567689 A 1996 ✓
- (8) Von Borstel; US 5583117 A 1996 ✓
- (9) Yamamoto, S; JP 09030976 A2 HCAPLUS

IT 58-96-8, Uridine


RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(uridine or uridine source for increasing cytidine levels in vivo and treating cytidine-dependent human **neurol.** diseases)

RN 58-96-8 HCAPLUS

CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 54-03-5, Hexobendine 62-49-7, Choline  
67-48-1, Choline chloride 87-67-2,  
Choline bitartrate 563-24-6,  
Glycerophosphatidylcholine 563-24-6D,  
Glycerophosphocholine, acyl derivs. 987-78-0, CDP-  
choline 5909-45-5 5909-45-5D, derivs.  
5983-09-5, 2',3'-Dideoxyuridine 23464-76-8,  
Choline stearate 26287-69-4, L-Uridine  
35898-87-4, Dilazep 153547-98-9

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)  
 (uridine or uridine source for increasing cytidine  
 levels in vivo and treating cytidine-dependent human **neuro**l.  
 diseases)


RN 54-03-5 HCAPLUS

CN Benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediylbis[(methylimino)-3,1-propanediyl] ester (9CI) (CA INDEX NAME)




RN 62-49-7 HCAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl- (9CI) (CA INDEX NAME)



RN 67-48-1 HCAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

RN 87-67-2 HCAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (2R,3R)-2,3-dihydroxybutanedioic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 49681-69-8

CMF C4 H5 O6

CDES 1:R2:R\*,R\*


Absolute stereochemistry.



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 563-24-6 HCAPLUS

CN Ethanaminium, 2-[[ (2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 563-24-6 HCAPLUS


CN Ethanaminium, 2-[[ (2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 987-78-0 HCAPLUS


CN Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl] ester, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 5909-45-5 HCAPLUS

CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 5909-45-5 HCAPLUS

CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 5983-09-5 HCAPLUS  
 CN Uridine, 2',3'-dideoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 23464-76-8 HCAPLUS  
 CN Ethanaminium, N,N,N-trimethyl-2-[(1-oxooctadecyl)oxy]- (9CI) (CA INDEX NAME)



RN 26287-69-4 HCAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-.beta.-L-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 35898-87-4 HCAPLUS  
 CN Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 153547-98-9 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L48 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:635462 HCAPLUS

DN 131:237984

TI **uridine** for treatment of neuron degenerative diseases

IN Piazza, Cinzia; Politi, Vincenzo; Materazzi, Mario

PA Polifarma S.p.A., Italy

SO U.S., 7 pp.

CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K031-55  
 NCL 514269000  
 CC 1-11 (Pharmacology)  
 Section cross-reference(s): 63  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5962459	A	19991005	US 1997-862306	19970523
PRAI	US 1996-18543		19960529		

AB **Uridine** is a therapeutic agent active as a growth promoter for treatment of neuron degenerative diseases deriving from pathol. aging or selective destruction. In particular, **uridine** shows the same biol. effects as NGF, when added at low doses to the culture medium, so that **uridine** may replace NGF as therapeutic agent in neural diseases and it may be also assocd. with other growth factors that allow differentiation of neurons, or with antitumor and antiviral drugs that cause neuron damage. In addn. **uridine** shows important trophic properties on various types of cultured cells, stimulating cell reprodn. when used at rather high dose levels.

ST **uridine neurodegenerative** disease treatment

IT **Nervous** system  
 (amyotrophic lateral sclerosis; **uridine** for treatment of neuron degenerative diseases)

IT Anti-AIDS agents  
 (antiviral agent peripheral nervous-system-harming effect; **uridine** for treatment of neuron degenerative diseases)

IT Neurotrophic factors  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (brain-derived; **uridine** for treatment of neuron degenerative diseases)

IT Antitumor agents  
 (cell-harming effects; **uridine** for treatment of neuron degenerative diseases)

IT **Nervous** system  
 (degeneration; **uridine** for treatment of neuron degenerative diseases)

IT Neurotrophic factors  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (glial-derived; **uridine** for treatment of neuron degenerative diseases)

IT Antiviral agents  
 (peripheral nervous-system-harming effects; **uridine** for treatment of neuron degenerative diseases)

IT Nerve, disease  
 (peripheral neuropathy; **uridine** for treatment of neuron degenerative diseases)

IT **Nervous** system  
 (peripheral; **uridine** for treatment of neuron degenerative diseases)

IT **Brain**, disease  
 (stroke, nervous system disturbance from; **uridine** for treatment of neuron degenerative diseases)

IT Anti-**Alzheimer's** agents  
**Antiparkinsonian** agents

Cell differentiation  
 Cell proliferation  
 Drug delivery systems  
 Drug interactions

**Nervous** system agents  
 Neuroglia  
 Neuron

(**uridine** for treatment of neuron degenerative diseases)

IT Ciliary neurotrophic factor  
Growth factors, animal  
Neurotrophic factors  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(**uridine** for treatment of neuron degenerative diseases)

IT Transforming growth factors  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(.beta.-; **uridine** for treatment of neuron degenerative diseases)

IT 7481-89-2, DdC 30516-87-1, AZT  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**uridine** for treatment of neuron degenerative diseases)


IT **58-96-8, Uridine** 9061-61-4, Nerve growth factor  
62031-54-3, Fibroblast growth factor 67763-96-6; Insulin-like growth factor 1 130939-66-1, Neurotrophin 3 143375-33-1, Neurotrophin 4 148499-03-0, Neurotrophin 5  
RL: BAC (Biological activity or effector, except adverse); THU  
(**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(**uridine** for treatment of neuron degenerative diseases)

RE.CNT 11  
RE  
(1) Agnati; Acta Physiol Scand 1986, V126(4), P525 HCAPLUS  
(2) Anon; EP 0178267 1986 HCAPLUS  
(3) Anon; EP 0348360 1989 HCAPLUS  
(4) Anon; EP 0462075 1991 HCAPLUS  
(5) Anon; JP 05304951 1993 HCAPLUS  
(6) Benzi, G; Biochemical Pharmacology 1983, V32(6), P1083 HCAPLUS  
(7) Engal, W; Neurology 1988, V38(3, supplement 1), P326  
(8) Keilbaugh, S; Molec Pharmacology 1993, V44(4), P702 HCAPLUS  
(9) Merck & Co; The Merck Index, Twelfth Edition 1996, P1113  
(10) Mervis; Ann NY Acad Sci 1991, P95 HCAPLUS  
(11) Wakade, T; Journal of Physiology 1995, V488(1), P123 HCAPLUS

IT **58-96-8, Uridine**  
RL: BAC (Biological activity or effector, except adverse); THU  
(**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(**uridine** for treatment of neuron degenerative diseases)

RN 58-96-8 HCAPLUS  
CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L48 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2000 ACS  
AN 1999:184143 HCAPLUS  
DN 130:218318  
TI Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons  
IN Benowitz, Larry I.  
PA Children's Medical Center Corporation, USA  
SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-70  
 ICS A61K031-52  
 CC 1-11 (Pharmacology)  
 Section cross-reference(s): 63  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911274	A1	19990311	WO 1998-US3001	19980220
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9866568	A1	19990322	AU 1998-66568	19980220
	EP 1009412	A1	20000621	EP 1998-908565	19980220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-921902		19970902		
	WO 1998-US3001		19980220		
AB	Methods and compns. for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic <b>Brain</b> Injury, <b>cerebral</b> aneurism, <b>spinal</b> cord injury and the like) and methods for inhibiting the axonal outgrowth of central nervous system neurons in conditions such as epilepsy, e.g., post-traumatic epilepsy, and neuropathic pain syndrome, are also provided. These methods generally involve contacting the central nervous system neurons with a purine nucleoside, or analog thereof. Preferably, inosine or guanosine is used to stimulate axonal outgrowth and 6-thioguanine is used to inhibit axonal outgrowth. The methods and compns. are particularly useful for modulating the axonal outgrowth of mammalian central nervous system neurons, such as mammalian retinal ganglion cells. Pharmaceutical and packaged formulations that include the purine nucleosides, and analogs thereof, of the invention are also provided.				
ST	purine nucleoside pharmaceutical axon outgrowth; nervous system agent				
IT	purine nucleoside axon				
IT	Meninges (cerebellomedullary cistern, drug administration to; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)				
IT	Aneurysm ( <b>cerebral</b> ; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)				
IT	Liquid dosage forms (drug delivery systems) (dispersions; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)				
IT	<b>Cerebral</b> ventricle <b>Cerebrospinal</b> fluid Lumbar <b>spinal</b> cord (drug administration to; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)				
IT	Lipids, biological studies Polymers, biological studies				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (formulations contg.; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)				
IT	Infusions (drug delivery systems) (minipumps; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)				

IT Pain  
(neuropathic; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)

IT Paralysis  
(paraplegia; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)

IT Epilepsy  
(post-traumatic; purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)

IT Analgesics  
Anticonvulsants  
**Brain** trauma  
Ganglion cell (retinal)  
Liposomes (drug delivery systems)  
**Nervous** system agents  
Neurite outgrowth  
**Spinal** cord injury  
Stroke  
Sustained release drug delivery systems  
(purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)

IT Purine nucleosides  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)

IT 50-89-5, Thymidine, biological studies 56-65-5, 5'-ATP, biological studies 58-61-7, Adenosine, biological studies 58-63-9, Inosine 58-64-0, 5'-ADP, biological studies **58-96-8, Uridine** 60-92-4, **CAMP** 61-19-8, Adenosine 5'-monophosphate, biological studies 65-46-3, **Cytidine** 68-94-0, **Hypoxanthine** 69-89-6, Xanthine 85-31-4, 6-Thioguanosine 118-00-3, Guanosine, biological studies 131-99-7, 5'-Inosine monophosphate 146-77-0, 2-Chloroadenosine 362-74-3, Dibutyryl cAMP 7665-99-8, CGMP 31356-94-2, 8-Bromo cyclic GMP 38048-32-7 51350-19-7, erythro-9-(2-Hydroxy-3-nonyl)adenine 54364-02-2 152322-58-2  
RL: BAC (Biological activity or effector, except adverse); THU  
(**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)


RE.CNT 6

RE  
(1) Benowitz, L; DATABASE BIOSIS PREVIES 1997  
(2) Greene, L; J NEUROSCI 1990, V10(5) HCAPLUS  
(3) Gysbers, J; INT J DEV NEUROSCI 1996, V14(1) HCAPLUS  
(4) Gysbers, J; NEUROREPORT 1992, V3(11), P997 HCAPLUS  
(5) Medcament, P; WO 9400132 A 1994  
(6) Svensson, B; EUR J NEUROSCI 1993, V5(8) MEDLINE

IT **58-96-8, Uridine**  
RL: BAC (Biological activity or effector, except adverse); THU  
(**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(purine nucleosides and analogs for modulating the axonal outgrowth of central nervous system neurons)

RN 58-96-8 HCAPLUS  
CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L48 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1998:569857 HCAPLUS  
 DN 129:314450  
 TI A syndrome of seizures and pervasive **developmental disorder** associated with excessive cellular nucleotidase activity  
 AU Page, Theodore; Yu, Alice; Fontenessi, John; Nyhan, William  
 CS Dep. Neurosciences and Dep. Pediatrics, University California, La Jolla, CA, 92093, USA  
 SO Adv. Exp. Med. Biol. (1998), 431 (Purine and Pyrimidine Metabolism in Man IX, 1998), 789-792  
 CODEN: AEMBAP; ISSN: 0065-2598  
 PB Plenum Publishing Corp.  
 DT Journal  
 LA English  
 CC 14-10 (Mammalian Pathological Biochemistry)  
 AB A unique type of pervasive **developmental disorder** (PDD) is reported, which is assocd. with seizures and other neurol. symptoms, abnormal speech and behavior, and increased susceptibility to infection. All of these patients showed excessive 5'-nucleotidase in their fibroblast lysates. Metabolic therapy with oral **uridine** brought about dramatic improvement in every case.  
 ST **mental disorder** seizure nucleotidase **uridine**  
 IT **Mental disorders**  
     (pervasive **developmental disorder**; syndrome of seizures and pervasive **developmental disorder** assocd. with excessive cellular nucleotidase **activity**, in humans)  
 IT Seizures  
     (syndrome of seizures and pervasive **developmental disorder** assocd. with excessive cellular nucleotidase **activity**, in humans)  
 IT Purine nucleotides  
     Pyrimidine nucleotides  
 RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)  
     (syndrome of seizures and pervasive **developmental disorder** assocd. with excessive cellular nucleotidase **activity**, in humans)  
 IT 64-18-6, Formic acid, biological studies  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
     (incorporation into pyrimidine nucleotides; syndrome of seizures and pervasive **developmental disorder** assocd. with excessive cellular nucleotidase **activity**, in humans)  
 IT 9027-73-0, 5'-Nucleotidase  
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
     (syndrome of seizures and pervasive **developmental disorder** assocd. with excessive cellular nucleotidase **activity**, in humans)  
 IT 58-96-8, Uridine  
 RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
     (syndrome of seizures and pervasive **developmental disorder**

**disorder** assocd. with excessive cellular nucleotidase activity,  
in humans)

IT **58-96-8, Uridine**

RL: BPR (Biological process); **THU (Therapeutic use)**; BIOL  
(Biological study); PROC (Process); USES (Uses)


(syndrome of seizures and pervasive **developmental**

**disorder** assocd. with excessive cellular nucleotidase activity,  
in humans)

RN 58-96-8 HCAPLUS

CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L48 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2000 ACS

AN 1997:803819 HCAPLUS

DN 128:30410

TI **Uridine**-comprising therapeutic active agent for treatment of  
**neurodegenerative** disorders

IN Piazza, Cinzia; Politi, Vincenzo

PA Polifarma S.P.A., Italy

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-70

CC 1-11 (Pharmacology)

Section cross-reference(s): 2, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9745127	A1	19971204	WO 1997-IT117	19970523
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9730468	A1	19980105	AU 1997-30468	19970523
	EP 914131	A1	19990512	EP 1997-925266	19970523
	R: AT, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT, FI				
	BR 9709379	A	20000111	BR 1997-9379	19970523
	JP 2000503668	T2	20000328	JP 1997-541970	19970523
PRAI	IT 1996-RM364		19960528		
	WO 1997-IT117		19970523		


AB **Uridine** is a therapeutic agent active as a growth promoter for treatment of neuron degenerative diseases deriving from pathol. ageing or selective destruction. In particular **uridine** shows the same biol. effects as NGF when added at low doses to the culture medium, so that **uridine** may replace NGF as therapeutic agent in neural diseases and it may be also assocd. to other growth factors that allow neuron's differentiation, or with anti-cancer and anti-virus drugs that cause neuron damage. In addn. **uridine** shows important trophic

properties on various types of cultured cells, stimulating cell reprodn. when used at rather high dose levels.

- ST **neurodegenerative** disease therapeutic **uridine**
- IT Peripheral neuropathy  
(iatrogenic; **uridine** for treatment of **neurodegenerative** disorders)
- IT **Brain**-derived neurotrophic factor  
Ciliary neurotrophic factor  
Glial-derived neurotrophic factor  
Neurotrophic factors  
Transforming growth factors .beta.  
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(mimic for; **uridine** for treatment of **neurodegenerative** disorders)
- IT AIDS (disease)  
(peripheral nervous system disorder from virucide against; **uridine** for treatment of **neurodegenerative** disorders)
- IT Antiviral agents  
(peripheral nervous system disorder from; **uridine** for treatment of **neurodegenerative** disorders)
- IT Antitumor agents  
(peripheral neuropathy from; **uridine** for treatment of **neurodegenerative** disorders)
- IT **Alzheimer's** disease  
Amyotrophic lateral sclerosis  
Cell proliferation  
Differentiation inducers  
Drug delivery systems  
Glial cells  
**Nervous** system agents  
**Neurodegenerative** diseases  
Neuroprotectants  
Neurotoxicity  
**Parkinson's** disease  
Stroke  
(**uridine** for treatment of **neurodegenerative** disorders)
- IT 9061-61-4, Nerve growth factor 62031-54-3, Fibroblast growth factor 67763-96-6, Insulin-like growth factor I 130939-66-1, Neurotrophin 3 143375-33-1, Neurotrophin 4 148499-03-0, Neurotrophin 5  
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(mimic for; **uridine** for treatment of **neurodegenerative** disorders)
- IT 7481-89-2, DdC 30516-87-1, AZT  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
(toxicity; **uridine** for treatment of **neurodegenerative** disorders)
- IT **58-96-8, Uridine**  
RL: BAC (Biological activity or effector, except adverse); THU (**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(**uridine** for treatment of **neurodegenerative** disorders)
- IT **58-96-8, Uridine**  
RL: BAC (Biological activity or effector, except adverse); THU (**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(**uridine** for treatment of **neurodegenerative** disorders)
- RN 58-96-8 HCAPLUS
- CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.





L48 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2000 ACS

AN 1997:772604 HCAPLUS

DN 128:43875

TI Solution and process for resuscitation and reparation of  
**ischemically** damaged tissue

IN Brasile, Lauren

PA Breonics, Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A01N001-02

ICS A61M001-00; A61M031-00

CC 1-12 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9743899	A1	19971127	WO 1997-US8205	19970516 <--
	W: AU, CA, CN, JP, RU				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2255657	AA	19971127	CA 1997-2255657	19970516 <--
	AU 9730671	A1	19971209	AU 1997-30671	19970516 <--
	CN 1226132	A	19990818	CN 1997-195768	19970516 <--
	EP 1021084	A1	20000726	EP 1997-925571	19970516 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1996-649200		19960517 <--		
	WO 1997-US8205		19970516 <--		

AB A process and resuscitation soln. are disclosed for inducing repair of **ischem.** damaged organs and tissues, to the degree that impairment of function can be reversed; and preventing further tissue damage during restoration of the circulation of the treated organ or tissue. The process comprises flushing the organ with the resuscitation soln. of the invention at a warm temp. of approx. 28-37.degree.C to remove accumulated blood and acidotic products from blood flow deprivation; and perfusing the flushed organ or tissue with the resuscitation soln., wherein the soln. contains a novel combination of components to provide for (i) dilating of the blood vessels within the organ or tissue, (ii) reestablishing organ or tissue function by supplying trophic factors, (iii) restoring cellular integrity and function to the **ischem.** damaged organ or tissue, and (i.v.) reestablishing oxidative metab. by readapting the **ischem.** damaged organ or tissue, surviving by anaerobic respiration, to an oxygenated resuscitation soln.

ST tissue organ **ischemia** resuscitation; soln resuscitation **ischemia** tissue organ

IT Prostaglandins

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(I; soln. and process for resuscitation and reparation of **ischem.** damaged tissue)

IT Acidosis

(acidotic products; soln. and process for resuscitation and reparation of **ischem.** damaged tissue)

IT Renal transplant  
(allograft; soln. and process for resuscitation and reparation of  
**ischem.** damaged tissue)

IT Electron transport system (biological)  
Tricarboxylic acid cycle  
(components; soln. and process for resuscitation and reparation of  
**ischem.** damaged tissue)

IT Nucleic acids  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(derivs.; soln. and process for resuscitation and reparation of  
**ischem.** damaged tissue)

IT Energy metabolism (animal)  
(energy substrates; soln. and process for resuscitation and reparation  
of **ischem.** damaged tissue)

IT Allograft  
Autotransplant  
(kidney; soln. and process for resuscitation and reparation of  
**ischem.** damaged tissue)

IT Flow  
(rate; soln. and process for resuscitation and reparation of  
**ischem.** damaged tissue)

IT Respiration (animal)  
Therapy  
(resuscitation; soln. and process for resuscitation and reparation of  
**ischem.** damaged tissue)

IT **Anti-ischemic** agents  
Antioxidants  
Blood  
Blood pressure  
Blood vessel  
Calcium channel blockers  
Erythrocyte  
**Neuroprotectants**  
Oxidative metabolism  
Perfusion  
Pumps  
Renal **ischemia**  
Respiratory air  
Solutions (drug delivery systems)  
Vascular resistance  
Vasodilators  
pH  
(soln. and process for resuscitation and reparation of **ischem**  
. damaged tissue)

IT Amino acids, biological studies  
Hemoglobins  
Nucleosides, biological studies  
Perfluoro compounds  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(soln. and process for resuscitation and reparation of **ischem**  
. damaged tissue)

IT Vascular endothelium  
(substrates for endothelial cell-mediated vasodilation; soln. and  
process for resuscitation and reparation of **ischem.** damaged  
tissue)

IT Microvessel  
(substrates for microvessel vasodilation; soln. and process for  
resuscitation and reparation of **ischem.** damaged tissue)

IT Growth factors (animal)  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(trophic factors; soln. and process for resuscitation and reparation of  
**ischem.** damaged tissue)

IT 73-24-5D, Adenine, derivs.

RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(adenine compd. pool components; soln. and process for resuscitation  
and reparation of **ischem.** damaged tissue)

IT 7782-44-7, Oxygen, biological studies  
RL: BPR (Biological process); BSU (Biological study, unclassified); THU  
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(and oxygenators and oxygen carriers; soln. and process for  
resuscitation and reparation of **ischem.** damaged tissue)


IT 50-89-5, Thymidine, biological studies 50-99-7, Glucose, biological  
studies 51-84-3, **Acetylcholine**, biological studies 52-53-9,  
Verapamil 53-84-9, NAD 56-65-5, Adenosine triphosphate, biological  
studies 58-61-7, Adenosine, biological studies 58-68-4, NADH  
**58-96-8, Uridine** 61-19-8, Adenosine monophosphate,  
biological studies 63-39-8, UTP 65-46-3, Cytidine 70-18-8,  
Glutathione, biological studies 74-79-3, L-Arginine, biological studies  
85-61-0, Coenzyme A, biological studies 118-00-3, Guanosine, biological  
studies 127-17-3, Pyruvic acid, biological studies 146-14-5, Flavin  
adenine dinucleotide 154-87-0, Thiamine pyrophosphate chloride  
951-77-9, Deoxycytidine 958-09-8, Deoxyadenosine 961-07-9,  
Deoxyguanosine 7439-95-4, Magnesium, biological studies 9004-10-8,  
Insulin, biological studies 9005-49-6, Heparin, biological studies  
9007-28-7, Chondroitin sulfate 12619-70-4, Cyclodextrin 16887-00-6,  
Chloride, biological studies 106096-92-8, Acidic fibroblast growth  
factor 106096-93-9, Basic fibroblast growth factor  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(soln. and process for resuscitation and reparation of **ischem**  
. damaged tissue)

IT 124-38-9, Carbon dioxide, biological studies  
RL: BOC (Biological occurrence); BPR (Biological process); BIOL  
(Biological study); OCCU (Occurrence); PROC (Process)  
(soln. and process for resuscitation and reparation of **ischem**  
. damaged tissue)

IT **58-96-8, Uridine**  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(soln. and process for resuscitation and reparation of **ischem**  
. damaged tissue)

RN 58-96-8 HCAPLUS  
CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L48 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2000 ACS  
AN 1997:672984 HCAPLUS  
DN 127:344939  
TI **Developmental disorder** associated with increased  
cellular nucleotidase activity  
AU Page, Theodore; Yu, Alice; Fontanesi, John; Nyhan, William L.  
CS Departments Neurosciences Pediatrics, University California San Diego, La  
Jolla, CA, 92093, USA  
SO Proc. Natl. Acad. Sci. U. S. A. (1997), 94(21), 11601-11606  
CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences  
 DT Journal  
 LA English  
 CC 14-14 (Mammalian Pathological Biochemistry)  
 AB Four unrelated patients are described with a syndrome that included developmental delay, seizures, **ataxia**, recurrent infections, severe language deficit, and an unusual behavioral phenotype characterized by hyperactivity, short attention span, and poor social interaction. These manifestations appeared within the first few years of life. Each patient displayed abnormalities on EEG. No unusual metabolites were found in plasma or urine, and metabolic testing was normal except for persistent hypouricosuria. Investigation of purine and pyrimidine metab. in cultured fibroblasts derived from these patients showed normal incorporation of purine bases into nucleotides but decreased incorporation of **uridine**. De novo synthesis of purines and cellular phosphoribosyl pyrophosphate content also were moderately decreased. The distribution of incorporated purines and pyrimidines did not reveal a pattern suggestive of a deficient enzyme activity. Assay of individual enzymes in fibroblast lysates showed no deficiencies. However, the activity of cytosolic 5'-nucleotidase was elevated 6- to 10-fold. Based on the possibility that the obsd. increased catabolic activity and decreased pyrimidine salvage might be causing a deficiency of pyrimidine nucleotides, the patients were treated with oral pyrimidine nucleoside or nucleotide compds. All patients showed remarkable improvement in speech and behavior as well as decreased seizure activity and frequency of infections. A double-blind placebo trial was undertaken to ascertain the efficacy of this supplementation regimen. Upon replacement of the supplements with placebo, all patients showed rapid regression to their pretreatment states. These observations suggest that increased nucleotide catabolism is related to the symptoms of these patients, and that the effects of this increased catabolism are reversed by administration of **uridine**.

ST nucleotidase **development disorder**  
 IT **Ataxia**  
 Behavior (animal)  
**Brain** electric activity  
 Seizures  
     (**developmental disorder** assocd. with increased cellular nucleotidase activity in humans)

IT Pyrimidine nucleotides  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
     (**developmental disorder** assocd. with increased cellular nucleotidase activity in humans)

IT **Development** (mammalian postnatal)  
     (**disorder; developmental disorder** assocd. with increased cellular nucleotidase activity in humans)

IT 9027-73-0, 5'-Nucleotidase  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
     (**developmental disorder** assocd. with increased cellular nucleotidase activity in humans)

IT 7540-64-9, Phosphoribosyl pyrophosphate  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
     (**developmental disorder** assocd. with increased cellular nucleotidase activity in humans)

IT **58-96-8, Uridine**  
 RL: BPR (Biological process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)  
     (**developmental disorder** assocd. with increased cellular nucleotidase activity in humans)

IT **58-96-8, Uridine**  
 RL: BPR (Biological process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)  
     (**developmental disorder** assocd. with increased cellular nucleotidase activity in humans)

RN 58-96-8 HCAPLUS  
 CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

